Search Results
Jun 08, 2026, 07:00 ET RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
prostate cancer in combination with Bayer's darolutamide; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
small-molecule GLP-1) Preclinical ResultsADA Reference: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity (Abstract No.: 2543-P)IBI3042 is potentially the world's first once-weekly oral small-molecule GLP-1 receptor
More news about: Innovent Biologics
Jun 08, 2026, 04:00 ET sweelin® Clinical Trial Results Published in Leading Journal, Food Chemistry, Confirming Blood Glucose Safety
insulin, and GLP-1 levels were monitored for 120 minutes.All participants completed the study with no dropouts or test-item–related adverse events. The results confirmed that even high doses of sweelin® do not impact blood glucose, insulin, or GLP-1 levels in healthy individuals.These
More news about: Amai Proteins
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
development candidate for obesity treatment.2. Oral Small-Molecule GLP-1 Receptor Agonist: ASC30ASC30 is an oral, fully biased small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist with a chemical scaffold similar to that of orforglipron (OFG). In vitro
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:10 ET 歌禮ASC30臨床數據與ASC37、ASC39令人振奮的臨床前結果於美國糖尿病協會（ADA）2026年度科學會議齊亮相，夯實差異化肥胖管線
P-1R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，和ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：www.ascletis.com。詳情垂詢：
More news about: 歌禮製藥有限公司
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
the outcomes of amylin analogs alongside GLP-1 RAs. In the REIMAGINE clinical trial program, researchers evaluated CagriSema, a medication that combines two medications—cagrilintide, which mimics amylin and semaglutide, a GLP-1 RA. The REIMAGINE studies are all randomized phase
More news about: American Diabetes Association
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
GLP-1 combination therapy that addresses blood glucose control with reductions in bodyweight for people living with type 2 diabetes."Amylin, a pancreatic hormone co-secreted with insulin in response to food intake, plays a distinct yet complementary role to GLP-1, with
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
Real-World HbA1c and Weight Change 6 and 12 Months by GLP-1 Treatment Persistence in Adults with Type 2 DiabetesAbstract #1665-P, Presented Sunday, June 7Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals
More news about: Amgen
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
1,063 patients, 673 (63%) had a history of diabetes (median A1C 7.3%; diabetes duration nine years; 25% on glucagon-like peptide-1 receptor agonists [GLP-1RAs] and 37% on insulin). Baseline TG levels were similar in patients with diabetes (median 784 mg/dL) compared to those without diabetes (807 mg/dL;
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
validating the clinical advantages of the innovative cAMP-biased GLP-1 receptor agonist mechanism. By optimizing GLP-1 receptor signal transduction, it delivers superior clinical benefits over traditional GLP-1 receptor agonists, providing high-quality evidence-based medical
More news about: Sciwind Biosciences Co., Ltd.
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
data highlight the potential benefits of survodutide, a once-weekly injectable therapy targeting both the glucagon and glucagon-like peptide-1 (GLP-1) receptors in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as a fatty liver
More news about: American Diabetes Association
Jun 07, 2026, 14:30 ET 頭對頭：埃諾格魯肽體重降幅顯著優於司美格魯肽35%
基礎研究到惠及患者的臨床產品，我們將堅守科學轉化的初心，讓更多前沿科學成果真正落地為患者的健康福祉。」輝瑞全球高級副總裁、中國區總裁Jean-Christophe Pointeau表示：「我們很高興看到埃諾格魯肽在這一頭對頭研究中取得的令人矚目的臨床數據。該數據展現了新一代偏向型 GLP-1 在體重管理與代謝治療領域的突破性潛力。作為埃諾格魯肽商業化進程的主導方，輝瑞將充分發揮在中國市場積累的深厚經驗和資源優勢，加速推動這一創新療法落地，讓前沿科學真正惠及每一位需要的中國患者。」關於SLIMMER-UP-SWITCH頭對頭研究
More news about: 杭州先為達生物科技股份有限公司
Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
weight-related medical problems, to lose excess body weight and keep the weight off.Foundayo should not be used with other GLP-1 receptor agonist medicines.It is not known if Foundayo is safe and effective for use in children.Warnings – Foundayo
More news about: Eli Lilly and Company
Jun 07, 2026, 08:00 ET Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
2026 is IQVIA LRx, YTD based on week ending January 9, 2026 through May 15, 2026, with "new to GLP-1" based on 12 months look back for any other (obesity or diabetes) GLP-1 medicine (not including compounded products). IQVIA data of paid TRx and paid NBRx data were used to measure
More news about: NOVO NORDISK INC.
Jun 06, 2026, 14:45 ET 82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring
medication that helps remove excess glucose through the urine, while 40% were using an incretin-based medication, such as a GLP-1-based medication. Participants were randomly assigned to either use a CGM device (Dexcom G7) or receive routine care with standard blood glucose meter
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
diabetes and obesity phase 3 study results for retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1(GLP-1), and glucagon triple hormone receptor agonist, were announced today. The findings demonstrated positive outcomes in people living with obesity
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
(orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain,
More news about: Eli Lilly and Company
Jun 06, 2026, 09:00 ET Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
/PRNewswire/ -- New data highlight the potential benefits of using berobenatide, an investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) across patient populations—including in individuals with excess weight or obesity with or without type 2 diabetes—and dosage levels, ranging
More news about: American Diabetes Association
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
drove a remarkable 69% reduction in fat mass (compared to 47% with semaglutide alone), without worsening the muscle depletion typically caused by GLP-1s.Significant Liver Health Benefits: The therapy dose-dependently reduced liver triglycerides by up to 79%, demonstrating deep resolution
More news about: Ractigen Therapeutics
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
June 5, 2026 /PRNewswire/ -- Ambrosia Biosciences Inc. ("Ambrosia"), today announced preclinical data supporting its small molecule GLP-1 receptor agonist development candidate, AMB-702, in a poster presentation at the American Diabetes Association's (ADA) 86th Scientific Sessions.
More news about: Ambrosia Biosciences
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.1 Presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans,
More news about: NOVO NORDISK INC.
Jun 05, 2026, 18:30 ET First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
complications such as heart and kidney disease, creating a significant unmet need for non-insulin therapies. Dual GIP/GLP-1 RAs mimic the naturally occurring GLP-1 and GIP hormones and can help regulate blood glucose, reduce appetite, stimulate insulin release after eating, and
More news about: American Diabetes Association
Jun 05, 2026, 08:00 ET Global Consensus Guides Safe Use of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Type 1 Diabetes
June 5, 2026 /PRNewswire/ -- A consensus statement providing novel guidance for use of GLP-1 and GLP-1/GIP receptor agonists (GLP-1s and GIP/GLP-1s) in management of type 1 diabetes (T1D) was
More news about: The diaTribe Foundation
Jun 05, 2026, 06:02 ET 13 Top Press Releases from May
Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US"With Ozempic® now available as both an injection
More news about: PR Newswire
Jun 04, 2026, 09:50 ET Barberitos Named to Fast Casual's 2026 Top 100 Movers & Shakers List as Development Pipeline Reaches 32 Restaurants
openings planned for 2026Menu innovation initiatives, including limited-time offerings such as Birria Tacos and Mango Salsa, GLP-1-friendly menu options, and signature high-protein recipes.Flexible restaurant formats and streamlined operations designed for scalable growthStrategic
More news about: Barberitos